Skip to content

Total debt at other companies

Regenxbio logo
RegenxbioRGNX
$71.07M-11.0%
Xencor logo
XencorXNCR
$175.16M-21.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$13.61K-99.9%
Schrodinger logo
SchrodingerSDGR
$106.96M-7.9%
Pfizer logo
PfizerPFE
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $13.63M.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's total debt?
Sutro Biopharma (STRO) reported total debt of $13.63M in Q1 2026.
How has Sutro Biopharma's total debt changed year-over-year?
Sutro Biopharma's total debt decreased by 36.3% year-over-year, from $21.4M to $13.63M.
What is the long-term trend for Sutro Biopharma's total debt?
Over 5 years (2020 to 2025), Sutro Biopharma's total debt has grown at a -22.3% compound annual growth rate (CAGR), from $55.25M to $15.67M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.